BLU 956
Alternative Names: BLU-956Latest Information Update: 26 Jan 2024
At a glance
- Originator Blueprint Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research HER2 negative breast cancer